Neoadjuvant use of the aromatase inhibitor letrozole in uterine cancer: endocrine and clinical effects;Neoad''iuvantnoe primenenie ingibitora aromatazy letrozola pri rake tela matki: éndokrinnye i klinicheskie éffekty.

Voprosy onkologii

Volumn 47, Issue 5, 2001, Pages 571-574

  Bershtein, L M ^a   Maksimov, S I ^a   Gershfel'd, E D ^a   Gamaiunova, V B ^a   Tsyrlina, E V ^a   Meshkova, I E ^a   Kovalenko, I G ^a   Larionov, A A ^a   Kovalevskii, A I ^a   Vasil'ev, D A ^a  

^a N N PETROV RESEARCH INSTITUTE OF ONCOLOGY   (Russian Federation)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; AROMATASE INHIBITOR; ENZYME INHIBITOR; ESTRADIOL; FOLLITROPIN; LETROZOLE; LUTEINIZING HORMONE; NITRILE; PROGESTERONE RECEPTOR; TRIAZOLE DERIVATIVE;

ADJUVANT CHEMOTHERAPY; ARTICLE; BLOOD; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; METABOLISM; TREATMENT OUTCOME; UTERUS CANCER;

ANTINEOPLASTIC AGENTS; AROMATASE INHIBITORS; BLOOD GLUCOSE; CHEMOTHERAPY, ADJUVANT; ENZYME INHIBITORS; ESTRADIOL; FEMALE; FOLLICLE STIMULATING HORMONE; HUMANS; LUTEINIZING HORMONE; NITRILES; RECEPTORS, PROGESTERONE; TREATMENT OUTCOME; TRIAZOLES; UTERINE NEOPLASMS;

EID: 0035752611     PISSN: 05073758     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (0)